Alnylam Pharmaceuticals Inc.

MA · United States · Reporting entity ID 100000481817

Total reported 2019–2025

$197.5M

#60 of 2,960 reporting companies — 0.2% of all reported industry payments

$40.3M in general payments across 98,231 records, plus $157.2M in research funding across 81,050 records.

How it breaks down

General payments $40,260,635

Research funding $157,241,978

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.